Epitope distribution in ordered and disordered protein regions. Part B - Ordered regions and disordered binding sites are targets of T- and B-cell immunity

Journal of Immunological Methods

Volumn 407, Issue , 2014, Pages 90-107

  Pavlović, Mirjana D ^a   Jandrlić, Davorka R ^a   Mitić, Nenad S ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Autoimmunity; Cancer; Disorder prediction; Disordered binding sites; Epitope structural availability; T cell epitope prediction

Indexed keywords

AUTOANTIGEN; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN 1; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTRINSICALLY DISORDERED PROTEIN; MELANOMA ANTIGEN 4; SMALL NUCLEAR RIBONUCLEOPROTEIN; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CELLULAR IMMUNITY; CRYSTALLOGRAPHY; EPSTEIN BARR VIRUS; HUMAN; HUMORAL IMMUNITY; HYDROPHOBICITY; PREDICTION; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; T LYMPHOCYTE; VIRUS REPLICATION;

EUKARYOTA; HUMAN HERPESVIRUS 4;

AUTOIMMUNITY; CANCER; DISORDER PREDICTION; DISORDERED BINDING SITES; EPITOPE STRUCTURAL AVAILABILITY; T-CELL EPITOPE PREDICTION;

ANTIGENS, NEOPLASM; B-LYMPHOCYTES; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; NEOPLASM PROTEINS; PEPTIDES; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; RIBONUCLEOPROTEIN, U1 SMALL NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; TESTICULAR NEOPLASMS; TRANS-ACTIVATORS;

EID: 84901435424     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.03.027     Document Type: Article

References (80)

1. Avis J.M., Allain F.H., Howe P.W., Varani G., Nagai K., Neuhaus D. Solution structure of the N-terminal RNP domain of U1A protein: the role of C-terminal residues in structure stability and RNA binding. J. Mol. Biol. 1996, 257(2):398. 10.1006/jmbi.1996.0171.
2. Bei R., Masuelli L., Palumbo C., Modesti M., Modesti A. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth. Cancer Lett. 2009, 281(1):8. 10.1016/j.canlet.2008.11.009.
3. Blake N., Haigh T., Shaka'a G., Croom-Carter D., Rickinson A. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 2000, 165(12):7078.
4. Bochkarev A., Barwell J.A., Pfuetzner R.A., Furey W., Edwards A.M., Frappier L. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein EBNA 1. Cell 1995, 83(1):39.
5. Brendel V., Dohlman J., Blaisdell B.E., Karlin S. Very long charge runs in systemic lupus erythematosus-associated autoantigens. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(4):1536.
6. Brown S.A., Stambas J., Zhan X., Slobod K.S., Coleclough C., Zirkel A., Hurwitz J.L. Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity. J. Immunol. 2003, 171(8):4140.
7. Carl P.L., Temple B.R., Cohen P.L. Most nuclear systemic autoantigens are extremely disordered proteins: implications for the etiology of systemic autoimmunity. Arthritis Res. Ther. 2005, 7(6):R1360. 10.1186/ar1832.
8. Carmicle S., Steede N.K., Landry S.J. Antigen three-dimensional structure guides the processing and presentation of helper T-cell epitopes. Mol. Immunol. 2007, 44(6):1159. 10.1016/j.molimm.2006.06.014.
9. Chaves F.A., Richards K.A., Torelli A., Wedekind J., Sant A.J. Peptide-binding motifs for the I-Ad MHC class II molecule: alternate pH-dependent binding behavior. Biochemistry 2006, 45(20):6426. 10.1021/bi060194g.
10. Cheng Y., Oldfield C.J., Meng J., Romero P., Uversky V.N., Dunker A.K. Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry 2007, 46(47):13468. 10.1021/bi7012273.
11. Chianese-Bullock K.A., Russell H.I., Moller C., Gerhard W., Monaco J.J., Eisenlohr L.C. Antigen processing of two H2-IEd-restricted epitopes is differentially influenced by the structural changes in a viral glycoprotein. J. Immunol. 1998, 161(4):1599.
12. Dai G., Carmicle S., Steede N.K., Landry S.J. Structural basis for helper T-cell and antibody epitope immunodominance in bacteriophage T4 Hsp10. Role of disordered loops. J. Biol. Chem. 2002, 277(1):161. 10.1074/jbc.M102259200.
13. Dai Y.D., Carayanniotis G., Sercarz E. Antigen processing by autoreactive B cells promotes determinant spreading. Cell. Mol. Immunol. 2005, 2(3):169.
14. Demachi-Okamura A., Ito Y., Akatsuka Y., Tsujimura K., Morishima Y., Takahashi T., Kuzushima K. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Sci. 2008, 99(8):1633. 10.1111/j.1349-7006.2008.00852.x.
15. Depil S., Morales O., Castelli F.A., Delhem N., Francois V., Georges B., Pancre V. Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies. J. Immunother. 2007, 30(2):215. 10.1097/01.cji.0000211338.99137.4f.
16. Destro F., Sforza F., Sicurella M., Marescotti D., Gallerani E., Baldisserotto A., Gavioli R. Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells. Immunology 2011, 133(1):105. 10.1111/j.1365-2567.2011.03416.x.
17. Dosztanyi Z., Csizmok V., Tompa P., Simon I. IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 2005, 21(16):3433. 10.1093/bioinformatics/bti541.
18. Dosztanyi Z., Meszaros B., Simon I. Bioinformatical approaches to characterize intrinsically disordered/unstructured proteins. Brief. Bioinform. 2010, 11(2):225. 10.1093/bib/bbp061.
19. Frappier L. The Epstein-Barr Virus EBNA1 protein. Scientifica 2012, 2012:1. 10.6064/2012/438204.
20. Halling-Brown M., Shaban R., Frampton D., Sansom C.E., Davies M., Flower D., Moss D.S. Proteins accessible to immune surveillance show significant T-cell epitope depletion: implications for vaccine design. Mol. Immunol. 2009, 46(13):2699. 10.1016/j.molimm.2009.05.027.
21. Harley J.B., James J.A. Epstein-Barr virus infection induces lupus autoimmunity. Bull. NYU Hosp. Jt. Dis. 2006, 64(1-2):45.
22. Harley J.B., James J.A. Everyone comes from somewhere: systemic lupus erythematosus and Epstein-Barr virus induction of host interferon and humoral anti-Epstein-Barr nuclear antigen 1 immunity. Arthritis Rheum. 2010, 62(6):1571. 10.1002/art.27421.
23. Hennard C., Pfuhl T., Buettner M., Becker K.F., Knofel T., Middeldorp J., Grasser F. The antibody 2B4 directed against the Epstein-Barr Virus (EBV)-encoded nuclear antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV association of human cancers. J. Pathol. 2006, 209(4):430. 10.1002/path.1996.
24. Holowaty M.N., Zeghouf M., Wu H., Tellam J., Athanasopoulos V., Greenblatt J., Frappier L. Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J. Biol. Chem. 2003, 278(32):29987. 10.1074/jbc.M303977200.
25. Hopp T.P., Woods K.R. Prediction of protein antigenic determinants from amino acid sequences. Proc. Natl. Acad. Sci. U. S. A. 1981, 78(6):3824.
26. Hsu W.L., Oldfield C., Meng J., Huang F., Xue B., Uversky V.N., Dunker A.K. Intrinsic protein disorder and protein-protein interactions. Pac. Symp. Biocomput. 2012, 116.
27. Iakoucheva L.M., Brown C.J., Lawson J.D., Obradovic Z., Dunker A.K. Intrinsic disorder in cell-signaling and cancer-associated proteins. J. Mol. Biol. 2002, 323(3):573.
28. James J.A., Harley J.B. Human lupus anti-spliceosome A protein autoantibodies bind contiguous surface structures and segregate into two sequential epitope binding patterns. J. Immunol. 1996, 156(10):4018.
29. James J.A., Gross T., Scofield R.H., Harley J.B. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J. Exp. Med. 1995, 181(2):453.
30. James J.A., Scofield R.H., Harley J.B. Lupus humoral autoimmunity after short peptide immunization. Ann. N. Y. Acad. Sci. 1997, 815:124.
31. Kofler M., Heuer K., Zech T., Freund C. Recognition sequences for the GYF domain reveal a possible spliceosomal function of CD2BP2. J. Biol. Chem. 2004, 279(27):28292. 10.1074/jbc.M402008200.
32. Kotta-Loizou I., Tsaousis G.N., Hamodrakas S.J. Analysis of Molecular Recognition Features (MoRFs) in membrane proteins. Biochim. Biophys. Acta 2013, 1834(4):798. 10.1016/j.bbapap.2013.01.006.
33. Kruger S., Schroers R., Rooney C.M., Gahn B., Chen S.Y. Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J. Immunother. 2003, 26(3):212.
34. Kyte J., Doolittle R.F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 1982, 157(1):105.
35. Landry S.J. Local protein instability predictive of helper T-cell epitopes. Immunol. Today 1997, 18(11):527.
36. Landry S.J. Helper T-cell epitope immunodominance associated with structurally stable segments of hen egg lysozyme and HIV gp120. J. Theor. Biol. 2000, 203(3):189. 10.1006/jtbi.1999.1056.
37. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity?. J. Exp. Med. 1995, 181(6):1945.
38. Lazarski C.A., Chaves F.A., Jenks S.A., Wu S., Richards K.A., Weaver J.M., Sant A.J. The kinetic stability of MHC class II: peptide complexes is a key parameter that dictates immunodominance. Immunity 2005, 23(1):29. 10.1016/j.immuni.2005.05.009.
39. Leen A., Meij P., Redchenko I., Middeldorp J., Bloemena E., Rickinson A., Blake N. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J. Virol. 2001, 75(18):8649.
40. Lobanov M.Y., Galzitskaya O.V. The Ising model for prediction of disordered residues from protein sequence alone. Phys. Biol. 2011, 8(3):035004. 10.1088/1478-3975/8/3/035004.
41. Long H.M., Haigh T.A., Gudgeon N.H., Leen A.M., Tsang C.W., Brooks J., Taylor G.S. CD4+ T-cell responses to Epstein-Barr Virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J. Virol. 2005, 79(8):4896. 10.1128/JVI.79.8.4896-4907.2005.
42. Lucchiari-Hartz M., Lindo V., Hitziger N., Gaedicke S., Saveanu L., van Endert P.M., Niedermann G. Differential proteasomal processing of hydrophobic and hydrophilic protein regions: contribution to cytotoxic T lymphocyte epitope clustering in HIV-1-Nef. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(13):7755. 10.1073/pnas.1232228100.
43. Marcar L., Maclaine N.J., Hupp T.R., Meek D.W. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res. 2010, 70(24):10362. 10.1158/0008-5472.CAN-10-1341.
44. Mcclain M.T., Lutz C.S., Kaufman K.M., Faig O.Z., Gross T.F., James J.A. Structural availability influences the capacity of autoantigenic epitopes to induce a widespread lupus-like autoimmune response. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(10):3551. 10.1073/pnas.0306267101.
45. Mcclain M.T., Poole B.D., Bruner B.F., Kaufman K.M., Harley J.B., James J.A. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum. 2006, 54(1):360. 10.1002/art.21682.
46. Melton S.J., Landry S.J. Three dimensional structure directs T-cell epitope dominance associated with allergy. Clin. Mol. Allergy 2008, 6:9. 10.1186/1476-7961-6-9.
47. Meszaros B., Simon I., Dosztanyi Z. Prediction of protein binding regions in disordered proteins. PLoS Comput. Biol. 2009, 5(5):e1000376. 10.1371/journal.pcbi.1000376.
48. Meszaros B., Dosztanyi Z., Simon I. Disordered binding regions and linear motifs-bridging the gap between two models of molecular recognition. PLoS One 2012, 7(10):e46829. 10.1371/journal.pone.0046829.
49. Mirano-Bascos D., Tary-Lehmann M., Landry S.J. Antigen structure influences helper T-cell epitope dominance in the human immune response to HIV envelope glycoprotein gp120. Eur. J. Immunol. 2008, 38(5):1231. 10.1002/eji.200738011.
50. Mitić N.S., Pavlović M.D., Jandrlić D.R. Epitope distribution in ordered and disordered protein regions - part A. T-cell epitope frequency, affinity and hydropathy. J. Immunol. Methods 2014, 406:83. 10.1016/j.jim.2014.02.012.
51. Mohan A., Oldfield C.J., Radivojac P., Vacic V., Cortese M.S., Dunker A.K., Uversky V.N. Analysis of molecular recognition features (MoRFs). J. Mol. Biol. 2006, 362(5):1043. 10.1016/j.jmb.2006.07.087.
52. Monneaux F., Muller S. Peptide-based immunotherapy of systemic lupus erythematosus. Autoimmun. Rev. 2004, 3(1):16. 10.1016/S1568-9972(03)00061-2.
53. Musson J.A., Walker N., Flick-Smith H., Williamson E.D., Robinson J.H. Differential processing of CD4 T-cell epitopes from the protective antigen of Bacillus anthracis. J. Biol. Chem. 2003, 278(52):52425. 10.1074/jbc.M309034200.
54. Nielsen M., Lundegaard C., Blicher T., Lamberth K., Harndahl M., Justesen S., Buus S. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One 2007, 2(8):e796. 10.1371/journal.pone.0000796.
55. Nielsen M., Lundegaard C., Blicher T., Peters B., Sette A., Justesen S., Lund O. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput. Biol. 2008, 4(7):e1000107. 10.1371/journal.pcbi.1000107.
56. Ohkuri T., Wakita D., Chamoto K., Togashi Y., Kitamura H., Nishimura T. Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells. Br. J. Cancer 2009, 100(7):1135. 10.1038/sj.bjc.6604966.
57. Oldfield C.J., Cheng Y., Cortese M.S., Brown C.J., Uversky V.N., Dunker A.K. Comparing and combining predictors of mostly disordered proteins. Biochemistry 2005, 44(6):1989. 10.1021/bi047993o.
58. Paludan C., Bickham K., Nikiforow S., Tsang M.L., Goodman K., Hanekom W.A., Munz C. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J. Immunol. 2002, 169(3):1593.
59. Radivojac P., Iakoucheva L.M., Oldfield C.J., Obradovic Z., Uversky V.N., Dunker A.K. Intrinsic disorder and functional proteomics. Biophys. J. 2007, 92(5):1439. 10.1529/biophysj.106.094045.
60. Rajagopalan K., Mooney S.M., Parekh N., Getzenberg R.H., Kulkarni P. A majority of the cancer/testis antigens are intrinsically disordered proteins. J. Cell. Biochem. 2011, 112(11):3256. 10.1002/jcb.23252.
61. Riemekasten G., Hahn B.H. Key autoantigens in SLE. Rheumatology (Oxford) 2005, 44(8):975. 10.1093/rheumatology/keh688.
62. Rothbard J.B., Taylor W.R. A sequence pattern common to T cell epitopes. EMBO J. 1988, 7(1):93.
63. Sakurai T., Itoh K., Higashitsuji H., Nagao T., Nonoguchi K., Chiba T., Fujita J. A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J. Biol. Chem. 2004, 279(15):15505. 10.1074/jbc.M310437200.
64. Sant A.J., Chaves F.A., Jenks S.A., Richards K.A., Menges P., Weaver J.M., Lazarski C.A. The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes. Immunol. Rev. 2005, 207:261. 10.1111/j.0105-2896.2005.00307.x.
65. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 2002, 188:22.
66. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 2004, 4(6):469. 10.1038/nri1372.
67. Sidney J., Peters B., Frahm N., Brander C., Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 2008, 9:1. 10.1186/1471-2172-9-1.
68. Sundar K., Jacques S., Gottlieb P., Villars R., Benito M.E., Taylor D.K., Spatz L.A. Expression of the Epstein-Barr virus nuclear antigen-1 (EBNA-1) in the mouse can elicit the production of anti-dsDNA and anti-Sm antibodies. J. Autoimmun. 2004, 23(2):127. 10.1016/j.jaut.2004.06.001.
69. Suskiewicz M.J., Sussman J.L., Silman I., Shaul Y. Context-dependent resistance to proteolysis of intrinsically disordered proteins. Protein Sci. 2011, 20(8):1285. 10.1002/pro.657.
70. Talken B.L., Schafermeyer K.R., Bailey C.W., Lee D.R., Hoffman R.W. T cell epitope mapping of the Smith antigen reveals that highly conserved Smith antigen motifs are the dominant target of T cell immunity in systemic lupus erythematosus. J. Immunol. 2001, 167(1):562.
71. Tompa P. Structure and Function of Intrinsically Disordered Proteins 2009, Chapman and Hall/CRC.
72. Toussirot E., Roudier J. Epstein-Barr virus in autoimmune diseases. Best Pract. Res. Clin. Rheumatol. 2008, 22(5):883. 10.1016/j.berh.2008.09.007.
73. Tsang C.W., Lin X., Gudgeon N.H., Taylor G.S., Jia H., Hui E.P., Rickinson A.B. CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes. J. Virol. 2006, 80(16):8263. 10.1128/JVI.00400-06.
74. Uversky V.N. The mysterious unfoldome: structureless, underappreciated, yet vital part of any given proteome. J. Biomed. Biotechnol. 2010, 2010:568068. 10.1155/2010/568068.
75. Uversky V.N., Dunker A.K. Understanding protein non-folding. Biochim. Biophys. Acta 2010, 1804(6):1231. 10.1016/j.bbapap.2010.01.017.
76. Uversky V.N., Gillespie J.R., Fink A.L. Why are "natively unfolded" proteins unstructured under physiologic conditions?. Proteins 2000, 41(3):415.
77. Voo K.S., Fu T., Heslop H.E., Brenner M.K., Rooney C.M., Wang R.F. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002, 62(24):7195.
78. Weaver J.M., Sant A.J. Understanding the focused CD4 T cell response to antigen and pathogenic organisms. Immunol. Res. 2009, 45(2-3):123. 10.1007/s12026-009-8095-8.
79. Weaver J.M., Lazarski C.A., Richards K.A., Chaves F.A., Jenks S.A., Menges P.R., Sant A.J. Immunodominance of CD4 T cells to foreign antigens is peptide intrinsic and independent of molecular context: implications for vaccine design. J. Immunol. 2008, 181(5):3039.
80. Welin Henriksson E., Wahren-Herlenius M., Lundberg I., Mellquist E., Pettersson I. Key residues revealed in a major conformational epitope of the U1-70K protein. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(25):14487.